PGEN Precigen Inc.

8.58
+0.38  (+5%)
Previous Close 8.2
Open 8.44
52 Week Low 1.26
52 Week High 11.1
Market Cap $1,758,083,313
Shares 204,904,815
Float 99,848,844
Enterprise Value $1,835,427,638
Volume 1,897,882
Av. Daily Volume 1,967,075
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
AG019
Type 1 diabetes
Phase 1/2
Phase 1/2
Phase 1b primary endpoint met demonstrating safety and tolerability - August 10, 2020.
PRGN-2009
HPV+ solid tumors
Phase 1/2
Phase 1/2
Phase 1/2 initial data presented January 13, 2021.
PRGN-2012
Recurrent Respiratory Papillomatosis (RRP)
Phase 1
Phase 1
Phase 1 trial to be initiated.
PRGN-3006
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Phase 1
Phase 1
Phase 1 initial data presented at ASH December 2020.
INXN-4001
Heart failure
Phase 1
Phase 1
Phase 1 trial met primary endpoint.
PRGN-3005
Ovarian cancer
Phase 1
Phase 1
Phase 1 initiation of dosing announced August 5, 2019.

Latest News

  1. GERMANTOWN, Md., March 1, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2020 financial results.

    "2021 promises to be another transformative year for our company with important data readouts and trial initiations anticipated for our key programs," said Helen Sabzevari, PhD, President and CEO of Precigen. "Through a combination of fiscal discipline and our recent capital raise, we have sufficient cash on hand to support our capital needs into 2023. We will continue to work diligently to advance our pipeline of innovative therapies and technology platforms as quickly as possible and our entire team remains committed to achieving this goal on behalf of the patients that motivate us every day. We look forward to providing updates in the coming months."

    Business Highlights:

    Healthcare Transition

    In January 2020, Precigen announced the change of the parent company's name to Precigen, Inc. from Intrexon Corporation to reflect the Company's tighter healthcare focus. The Company is now trading on Nasdaq under the stock symbol PGEN.

    Public Offering

    In January 2021, Precigen closed a public offering of 17,250,000 shares of common stock, which resulted in gross proceeds to Precigen of approximately $129.4 million before deducting the underwriting discount and other offering expenses payable by Precigen.

    PRGN-3005 UltraCAR-T®

    PRGN-3005 UltraCAR-T is a first-in-class investigational therapy under evaluation in an ongoing Phase 1/1b clinical study for the treatment of advanced, recurrent platinum resistant ovarian, fallopian tube or primary peritoneal cancer. Study subjects receive the PRGN-3005 infusion either via intraperitoneal (IP) (Arm A) or intravenous (IV) (Arm B) infusion (clinical trial identifier: NCT03907527). The study is being conducted in collaboration with the University of Washington and Fred Hutchinson Cancer Research Center.

    • Preliminary Clinical Data: In December 2020, Precigen reported preliminary Phase 1 data for patients at dose level 1 (n=3) and dose level 2 (n=3) in the IP arm. Data showed a favorable safety profile with no dose-limiting toxicities (DLTs), neurotoxicity or cytokine release syndromes (CRS) reported. PRGN-3005 UltraCAR-T cells showed encouraging expansion and persistence after low dose IP infusion without lymphodepletion. 50% (3 of 6) of patients experienced regression in total target tumor burden.
    • Enrollment Status: The Phase 1 trial is enrolling patients in the dose escalation phase of both the IP and IV arms. The dose expansion phase for the IP arm is anticipated to start in the second half of 2021.

    PRGN-3006 UltraCAR-T®

    PRGN-3006 UltraCAR-T is a first-in-class investigational therapy currently under clinical evaluation in an ongoing Phase 1/1b trial for the treatment of patients with relapsed or refractory (r/r) acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Study subjects receive the PRGN-3006 infusion either without prior lymphodepletion (Cohort 1) or following lymphodepleting chemotherapy (Cohort 2) (clinical trial identifier: NCT03927261). The study is being conducted in collaboration with H. Lee Moffitt Cancer Center & Research Institute.

    • Orphan Drug Designation: In January 2020, Precigen received US Food and Drug Administration (US FDA) Orphan Drug Designation for PRGN-3006 UltraCAR-T in patients with AML.
    • Preliminary Clinical Data: In December 2020, Precigen reported preliminary Phase 1 data for patients at dose level 1 (n=3) and dose level 2 (n=3) without prior lymphodepletion and dose level 1 (n=3) with lymphodepletion. Data showed a favorable safety profile with no DLTs or neurotoxicity. Encouraging expansion and persistence of PRGN-3006 UltraCAR-T was observed in both lymphodepletion and non-lymphodepletion cohorts and across all dose levels. PRGN-3006 treatment indicated clinical activity as evidenced by reduction in AML tumor blast levels.
      • The potential strength of the UltraCAR-T platform was highlighted at the American Society of Hematology (ASH) 2020 annual meeting with a case study of a patient with multiple prior treatment failures. Data showed that UltraCAR-T cells persisted for more than seven months after a very low dose, only 24 million total UltraCAR-T cells in the infusion, without prior lymphodepletion. This patient had stable disease and data showed a decline in blast levels in blood and bone marrow concomitant with UltraCAR-T expansion and persistence.
      • One of the patients treated with PRGN-3006 at dose level 1 in the lymphodepletion cohort, with approximately nine million UltraCAR-T cells, had an objective response and achieved complete remission with incomplete hematologic recovery (CRi) per European Leukemia Net (ELN) criteria.
    • Enrollment Status: The Phase 1 trial is enrolling patients in the dose escalation phase of both the lymphodepletion and non-lymphodepletion cohorts. A dose expansion phase is anticipated to start in the second half of 2021.

    UltraPorator™ 

    In 2020, Precigen announced its proprietary electroporation device, UltraPorator, designed to be a viable scale-up and commercialization solution for decentralized UltraCAR-T manufacturing. UltraPorator is a semi-closed, high-throughput system with a proprietary hardware and software solution and potentially represents a major advancement over current electroporation devices by significantly reducing the processing time and contamination risk.

    • FDA Clearance: In October 2020, Precigen announced that the US FDA cleared UltraPorator as a manufacturing device for its UltraCAR-T clinical trials.
    • First Patients Dosed with UltraCAR-T Cells Manufactured with UltraPorator: In November 2020, Precigen announced dosing of the first patients with UltraCAR-T cells manufactured using the UltraPorator system in the ongoing PRGN-3005 and PRGN-3006 Phase 1 clinical trials.

    AG019 ActoBiotics

    AG019 ActoBiotics is a novel investigational therapy designed to address the underlying cause of Type 1 diabetes (T1D) and is currently under clinical evaluation in an ongoing Phase 1b/2a clinical study for the treatment of early-onset T1D (clinical trial identifier: NCT03751007; EudraCT 2017-002871-24).

    • Phase 1b AG019 Monotherapy Clinical Data: In August 2020, Precigen ActoBio announced that the primary endpoint assessing safety and tolerability in the Phase 1b monotherapy portion of the study was met, and that preliminary results at six months after AG019 monotherapy treatment initiation showed an encouraging trend in the insulin C-peptide levels, a biomarker for T1D disease progression. Additional data announced in December 2020 showed that following a single 8-week treatment cycle of oral AG019, 58% (7 of 12) of the patients 17 years and older showed stabilization of C-peptide levels during the first 6 months and slower decline in C-peptide levels at 12 months compared to placebo. Results indicated the potential to preserve insulin production in early onset T1D through its capacity to induce antigen-specific immune modulation. The AG019 monotherapy treatment showed a favorable safety profile with no treatment discontinuations due to treatment emergent adverse events (TEAEs).
    • Interim Phase 2a Clinical Data: In December 2020, Precigen ActoBio announced interim data from the Phase 2a portion of the study showing the combination of AG019 and teplizumab had a favorable safety profile. Data showed that following the treatment with the combination of AG019 and teplizumab, 70% of the adult patients (7 of 10) showed stabilization of C-peptide levels at six months post treatment initiation with a trend towards higher C-peptide levels as compared to baseline levels.
    • Enrollment Status: Enrollment and dosing is complete in Phase 1b and Phase 2a portions of the study.

    PRGN-2009 AdenoVerse Immunotherapy

    PRGN-2009 is a first-in-class, off-the-shelf (OTS) investigational immunotherapy utilizing the AdenoVerse platform currently under clinical evaluation in an ongoing Phase 1/2 clinical study designed to activate the immune system to recognize and target HPV+ solid tumors (clinical trial identifier: NCT04432597). The study is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI).

    • IND Clearance: In April 2020, Precigen announced US FDA clearance of the IND to initiate the Phase 1/2 study.
    • First Patient Dosed: In August 2020, Precigen announced that the first patient was dosed in the Phase 1/2 study.
    • Preliminary Clinical Data: In January 2021, for the first time, Precigen provided preliminary Phase 1 data that showed that all patients (n=6) enrolled in the Phase 1 monotherapy arm have received multiple PRGN-2009 administrations and repeated administration of PRGN-2009 treatment has been well-tolerated with no DLTs. Preliminary correlative analysis from patients treated at dose level 1 (n=3) demonstrated an increase in HPV 16 and/or HPV 18-specific T-cell response post PRGN-2009 administration in 100% (3 of 3) of patients and an increase in the magnitude and breadth of immune response has been shown with respect to repeat administration of PRGN-2009.
    • Enrollment Status: The Phase 1 monotherapy arm has completed enrollment and the Phase 1 combination arm, which combines PRGN-2009 with M7824, is enrolling patients. Phase 2 enrollment is anticipated to initiate in the second half of 2021.

    PRGN-2012 AdenoVerse Immunotherapy

    PRGN-2012 is a first-in-class, investigational OTS AdenoVerse immunotherapy designed to elicit immune responses directed against cells infected with HPV 6 or HPV 11 for treatment of recurrent respiratory papillomatosis (RRP).

    • IND Clearance: In January 2021, Precigen announced the US FDA cleared the IND for the Phase 1 study (clinical trial identifier: NCT04724980) in adult patients with RRP. The study is being conducted under a CRADA with the Center for Cancer Research (CCR) at the NCI.
    • Preliminary Preclinical Data: In January 2021, Precigen presented data from preclinical studies in which PRGN-2012 was shown to induce robust HPV 6 and HPV 11-specific T-cell response in RRP patient samples in vitro.

    INXN-4001

    INXN-4001 is a multigenic investigational therapy for heart failure that uses a non-viral plasmid designed to constitutively express human SDF-1α, VEGF165, and S100A1 gene products to target the underlying molecular mechanisms of pathological myocardial remodelling. INXN-4001 is delivered to the ventricle via retrograde coronary sinus infusion (RCSI).

    • Interim Data at Six-Month Follow-up: In August 2020, Precigen Triple-Gene announced encouraging six-month follow-up data from twelve chronic heart failure patients treated in the Phase 1 study (clinical trial identifier: NCT03409627). Data showed that the study met the primary endpoints to evaluate safety and feasibility for INXN-4001 and the infusions of INXN-4001 were overall well tolerated. Preliminary data suggest an overall improvement in patient reported outcomes in 50% of patients six months after treatment.
    • Interim Data at 12-Month Follow-up: In January 2021, Precigen announced that the 12-month follow-up for Phase 1 clinical study is complete.

    Fourth Quarter 2020 Financial Highlights:

    • Revenues: Total revenues of $19.3 million in 2020 compared to $17.0 million in 2019;
    • Net Loss: Net loss from continuing operations of $39.7 million, or $(0.22) per basic share, of which $19.7 million was for non-cash charges in 2020 compared to net loss from continuing operations of $64.2 million, or $(0.41) per basic share, of which $32.9 million was for non-cash charges in 2019; and
    • Cash, Cash Equivalents, and Short-term Investments: Cash, cash equivalents, and short-term investments totaled $100.1 million as of December 31, 2020.

    Full Year 2020 Financial Highlights:

    • Revenues: Total revenues of $103.2 million in 2020 compared to $90.7 million in 2019; and
    • Net Loss: Net loss from continuing operations of $103.8 million, or $(0.62) per basic share, of which $45.9 million was for non-cash charges in 2020 compared to net loss from continuing operations attributable to Precigen of $168.7 million, or $(1.09) per basic share, of which $65.4 million was for non-cash charges in 2019.

    Fourth Quarter 2020 Financial Results Compared to Prior Year Period

    Total revenues increased $2.3 million, or 14%, over the quarter ended December 31, 2019. Service revenues increased $2.2 million due to increased customer demand at Trans Ova and Exemplar as well as the expansion of Trans Ova's commercial dairy business. Gross margin on services improved as a result of operational efficiencies gained through reductions in workforce earlier in the year and a reduction in third-party royalty rate obligations for certain licensed technologies.

    Research and development expenses decreased $2.8 million, or 21%, from the quarter ended December 31, 2019. Salaries, benefits, and other personnel costs decreased $1.8 million due to reductions in headcount at Precigen and its ActoBio subsidiary as Precigen deprioritized certain internal programs at its ActoBio subsidiary in 2019. Selling, general, and administrative ("SG&A") expenses increased $3.4 million, or 13%, and include a noncash $11.4 million loss on the settlement agreement with Harvest Intrexon Enterprise Funds in the current year as well as increased noncash share-based compensation expenses attributable to equity grants made in the first quarter of 2020. These increased costs were partially offset by decreases in fees payable to certain third-party vendors and a reduction in salaries, benefits, and other personnel costs following a 31% reduction in corporate headcount between the fourth quarter of 2019 and the fourth quarter of 2020 to support a more streamlined organization. There were also reductions in other corporate expenses as part of the streamlined organization and include the impact of the COVID-19 pandemic on travel.

    Full Year 2020 Financial Results Compared to Prior Year Period

    Total revenues increased $12.5 million, or 14%, over the year ended December 31, 2019 primarily due to an increase in collaboration and licensing revenues as the Company accelerated the recognition of previously deferred revenue upon the mutual termination of two of its collaboration agreements in 2020. Product and service revenues generated by Trans Ova and Exemplar increased $5.7 million due to an increase in services performed for new and existing customers and the expansion of Trans Ova's commercial dairy business. Gross margin on products and services improved as a result of operational efficiencies gained through reductions in workforce, improved inventory management, a reduction in third-party royalty rate obligations for certain licensed technologies, and a decrease in the cost of cows used in production. 

    Research and development expenses decreased $25.0 million, or 38%, from the year ended December 31, 2019. Salaries, benefits, and other personnel costs decreased $7.3 million and contract research organization costs and lab supplies decreased $13.9 million as Precigen deprioritized certain internal programs at its ActoBio subsidiary and closed two of its operating divisions in 2019. SG&A expenses decreased $6.9 million, or 7%, and include a net decrease in fees payable to certain third-party vendors and a reduction of 36% in corporate headcount to support a more streamlined organization. Other corporate expenses decreased $2.6 million as part of the streamlined organization and include the impact of the COVID-19 pandemic on travel. These decreases were partially offset by increased share-based compensation expense attributable to equity grants made in in the first quarter of 2020, one-time severance costs for terminated employees, and increased legal fees associated with litigation matters.

    Conference Call and Webcast

    Precigen will host a conference call today Monday, March 1st at 4:30 PM ET to discuss the financial results and provide a general business update. The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 9387943 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call. Participants may access the live webcast through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

    Precigen: Advancing Medicine with Precision

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

    Trademarks

    Precigen, UltraPorator, UltraCAR-T, ActoBiotics, AdenoVerse and Advancing Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of Precigen's business, including the timing, pace and progress of preclinical studies, clinical trials, discovery programs and related milestones, and the promise of the Company's portfolio of therapies, and in particular its CAR-T therapies. Although management believes that the plans, objectives and results reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, and actual future results may be materially different from the plans, objectives and expectations expressed. These risks and uncertainties include, but are not limited to, (i) the impact of the COVID-19 pandemic on our clinical trials, businesses, operating results, cash flows and/or financial condition, (ii) Precigen's strategy and overall approach to its health-focused business model; (iii) the ability to successfully enter new markets or develop additional products, including the expected timing and results of investigational studies and preclinical and clinical trials, including any delays or potential delays as a result of the COVID-19 pandemic, whether with its collaborators or independently; (iv) the ability to successfully enter into optimal strategic relationships with its subsidiaries and operating companies that it may form in the future; (v) the ability to hold or generate significant operating capital, including through partnering, asset sales and operating cost reductions; (vi) actual or anticipated variations in operating results; (vii) actual or anticipated fluctuations in competitors' or collaborators' operating results or changes in their respective growth rates; (viii) cash position; (ix) market conditions in Precigen's industry; (x) the volatility of Precigen's stock price; (xi) the ability, and the ability of collaborators, to protect Precigen's intellectual property and other proprietary rights and technologies; (xii) the ability, and the ability of collaborators, to adapt to changes in laws or regulations and policies, including federal, state, and local government responses to the COVID-19 pandemic; (xiii) outcomes of pending and future litigation; (xiv) the rate and degree of market acceptance of any products developed by Precigen, its subsidiaries, collaborations or joint ventures; (xv) the ability to retain and recruit key personnel; (xvi) expectations related to the use of proceeds from public offerings and other financing efforts; and (xvii) estimates regarding expenses, future revenue, capital requirements and needs for additional financing. For further information on potential risks and uncertainties, and other important factors, any of which could cause Precigen's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:

    Media Contact:

    Steven Harasym

    Glenn Silver

    Vice President, Investor Relations

    Lazar-FINN Partners

    Tel: +1 (301) 556-9850

     

     



     

    Precigen, Inc. and Subsidiaries

    Consolidated Balance Sheets

    (Unaudited)

    (Amounts in thousands)



    December 31, 2020





    December 31, 2019

    Assets















    Current assets















    Cash and cash equivalents



    $

    51,792





    $

    65,793

    Short-term investments





    48,325







    9,260

    Receivables















    Trade, net





    16,487







    20,650

    Related parties, net





    19







    600

    Notes





    3,689







    2,942

    Other





    232







    2,030

    Inventory





    11,359







    16,097

    Prepaid expenses and other





    7,192







    5,827

    Current assets held for sale or abandonment





    9,853







    111,444

    Total current assets





    148,948







    234,643

    Property, plant and equipment, net





    34,924







    43,952

    Intangible assets, net





    65,396







    68,346

    Goodwill





    54,363







    54,119

    Investments in affiliates











    1,461

    Right-of-use assets





    9,353







    11,803

    Other assets





    1,603







    1,349

    Noncurrent assets held for sale or abandonment











    40,090

    Total assets



    $

    314,587





    $

    455,763









    Liabilities and Shareholders' Equity















    Current liabilities















    Accounts payable



    $

    4,598





    $

    5,528

    Accrued compensation and benefits





    8,097







    13,198

    Other accrued liabilities





    9,549







    11,674

    Deferred revenue





    2,800







    5,697

    Lines of credit











    1,922

    Current portion of long-term debt





    360







    31,670

    Current portion of lease liabilities





    2,657







    2,634

    Related party payables





    19







    51

    Current liabilities held for sale or abandonment





    14,047







    50,538

    Total current liabilities





    42,127







    122,912

    Long-term debt, net of current portion





    171,522







    186,321

    Deferred revenue, net of current portion





    23,023







    48,136

    Lease liabilities, net of current portion





    7,744







    10,119

    Deferred tax liabilities





    2,897







    2,834

    Other long-term liabilities





    100







    Long-term liabilities held for sale or abandonment











    13,730

    Total liabilities





    247,413







    384,052

    Commitments and contingencies















    Shareholders' equity















    Common stock











    Additional paid-in capital





    1,886,567







    1,752,048

    Accumulated deficit





    (1,823,390)







    (1,652,869)

    Accumulated other comprehensive income (loss)





    3,997







    (27,468)

    Total shareholders' equity





    67,174







    71,711

    Total liabilities and shareholders' equity



    $

    314,587





    $

    455,763

     

    Precigen, Inc. and Subsidiaries

    Consolidated Statements of Operations

    (Unaudited)

    (Amounts in thousands, except share and per share data)





    Three months ended





    Year ended







    December 31,





    December 31,







    2020





    2019





    2020





    2019































    Revenues



























    Collaboration and licensing revenues



    $

    949



    $

    (658)



    $

    21,208



    $

    14,059



    Product revenues





    3,952





    5,297





    24,349





    23,780



    Service revenues





    14,284





    12,096





    56,899





    51,803



    Other revenues





    148





    267





    722





    1,080



    Total revenues





    19,333





    17,002





    103,178





    90,722































    Operating Expenses



























    Cost of products





    7,024





    7,800





    28,550





    31,930



    Cost of services





    6,766





    7,611





    26,963





    29,471



    Research and development





    10,671





    13,485





    41,644





    66,666



    Selling, general and administrative





    30,039





    26,646





    91,704





    98,634



    Impairment of goodwill









    29,642









    29,820



    Impairment of other noncurrent assets









    542





    920





    990



    Total operating expenses





    54,500





    85,726





    189,781





    257,511



    Operating loss





    (35,167)





    (68,724)





    (86,603)





    (166,789)































    Other Income (Expense), Net



























    Unrealized and realized appreciation in fair value of equity securities and preferred stock, net









    5,221









    8,291



    Interest expense





    (4,570)





    (4,542)





    (18,400)





    (17,666)



    Interest and dividend income





    426





    603





    2,451





    3,871



    Other income (expense), net





    (310)





    2,774





    (165)





    3,445



    Total other income (expense), net





    (4,454)





    4,056





    (16,114)





    (2,059)



    Equity in net loss of affiliates





    (13)





    (473)





    (1,138)





    (2,416)



    Loss from continuing operations before income taxes





    (39,634)





    (65,141)





    (103,855)





    (171,264)



    Income tax benefit





    (48)





    905





    82





    930



    Loss from continuing operations



    $

    (39,682)



    $

    (64,236)



    $

    (103,773)



    $

    (170,334)



    Loss from discontinued operations, net of income tax benefit





    (1,979)





    (104,979)





    (66,748)





    (153,582)



    Net loss



    $

    (41,661)



    $

    (169,215)



    $

    (170,521)



    $

    (323,916)



    Net loss attributable to the noncontrolling interests

















    1,592



    Net loss attributable to Precigen



    $

    (41,661)



    $

    (169,215)



    $

    (170,521)



    $

    (322,324)



    Amounts Attributable to Precigen



























    Net loss from continuing operations attributable to Precigen



    $

    (39,682)



    $

    (64,236)



    $

    (103,773)



    $

    (168,742)



    Net loss from discontinued operations attributable to Precigen





    (1,979)





    (104,979)





    (66,748)





    (153,582)



    Net loss attributable to Precigen



    $

    (41,661)



    $

    (169,215)



    $

    (170,521)



    $

    (322,324)



    Net Loss per Share



























    Net loss from continuing operations attributable to Precigen per share, basic and diluted



    $

    (0.22)



    $

    (0.41)



    $

    (0.62)



    $

    (1.09)



    Net loss from discontinued operations attributable to Precigen per share, basic and diluted





    (0.01)





    (0.68)





    (0.40)





    (1.00)



    Net loss attributable to Precigen per share, basic and diluted



    $

    (0.23)



    $

    (1.09)



    $

    (1.02)



    $

    (2.09)



    Weighted average shares outstanding, basic and diluted





    178,225,571





    155,230,741





    167,065,539





    154,138,774



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-reports-fourth-quarter-and-full-year-2020-financial-results-301237676.html

    SOURCE Precigen, Inc.

    View Full Article Hide Full Article
  2. GERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced the Company will release fourth quarter and full year 2020 financial results after the market closes on Monday, March 1, 2021.  The Company will host a conference call that day at 4:30 PM ET to discuss financial results and provide a general business update.

    The conference call may be accessed by dialing 1-888-317-6003 (Domestic US), 1-866-284-3684 (Canada) or 1-412-317-6061 (International) and providing the number 9387943 to join the Precigen Conference Call. Participants are asked to dial in 10-15 minutes in advance of the scheduled call time to facilitate timely connection to the call.

    Helen Sabzevari, PhD, President and CEO, will also present at the H.C. Wainwright Virtual Global Life Sciences Conference and the on-demand webcast will be available starting Tuesday, March 9, 2021 at 7:00 AM ET.

    Participants may register and access the webcasts for both events through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

    Precigen: Advancing Medicine with Precision

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

    Cautionary Statement Regarding Forward-Looking Statements 

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    Investor Contact:           

    Media Contact:                                      

    Steven Harasym              

    Glenn Silver

    Vice President, Investor Relations    

    Lazar-FINN Partners

    Tel: +1 (301) 556-9850       

      



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-to-announce-fourth-quarter-and-full-year-2020-financial-results-on-march-1st-301232765.html

    SOURCE Precigen, Inc.

    View Full Article Hide Full Article
  3. GERMANTOWN, Md., Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced Helen Sabzevari, PhD, President and CEO of Precigen, will participate in a virtual fireside chat at the Guggenheim Healthcare Talks Oncology Day on Friday, February 12, 2021 at 11:30 AM ET

    Participants may access the live webcast of the virtual event through Precigen's website in the Events & Presentations section at investors.precigen.com/events-presentations.

    Precigen: Advancing Medicine with Precision

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen and LinkedIn.

     

    Investor Contact:





    Media Contact:  

    Steven Harasym       





    Glenn Silver

    Vice President, Investor Relations       





    Lazar-FINN Partners

    Tel: +1 (301) 556-9850         





     







     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-to-participate-in-guggenheim-healthcare-talks-oncology-day-301222576.html

    SOURCE Precigen, Inc.

    View Full Article Hide Full Article
  4. GERMANTOWN, Md., Jan. 26, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 17,250,000 shares of its common stock at a public offering price of $7.50 per share, including the exercise in full by the underwriters of their option to purchase an additional 2,250,000 shares of common stock. Gross proceeds to Precigen from the offering were approximately $129.4 million before deducting the underwriting discount and other offering expenses payable by Precigen.

    Wells Fargo Securities and Stifel acted as joint book-running managers for the offering. JMP Securities acted as lead manager and H.C. Wainwright & Co. acted as co-manager for the offering.

    The public offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) and became effective on July 2, 2020. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus relating to the offering may also be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY 10001,  by telephone at (800) 326-5897, or by email at ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at .

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Precigen: Advancing Medicine with Precision

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies are designed to enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events. Various factors may cause differences between Precigen's expectations and actual results, including risks and uncertainties associated with market conditions. For further information on potential risks and uncertainties, and other important factors, any of which could cause Precigen's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    For more information, contact:



    Investor Contact:

    Media Contact:

    Steven Harasym                              

    Glenn Silver

    Vice President, Investor Relations   

    Lazar-FINN Partners

    Tel: +1 (301) 556-9850             

      



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-option-to-purchase-additional-shares-301215610.html

    SOURCE Precigen, Inc.

    View Full Article Hide Full Article
  5. GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. The offering is expected to close on January 26, 2021, subject to customary closing conditions.

    GERMANTOWN, Md., Jan. 22, 2021 /PRNewswire/ -- Precigen, Inc. (NASDAQ:PGEN) today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $7.50 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $112.5 million, excluding any exercise of the underwriters' option. The offering is expected to close on January 26, 2021, subject to customary closing conditions.

    Wells Fargo Securities and Stifel are acting as joint book-running managers for the offering with JMP Securities acting as lead manager and H.C. Wainwright & Co. acting as co-manager.

    Precigen intends to use the net proceeds from the offering to fund the development of clinical and preclinical product candidates and for working capital and other general corporate purposes.

    The public offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (SEC) and became effective on July 2, 2020. The final prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the final prospectus supplement, when available, and accompanying base prospectus relating to the offering may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500 West 33rd Street, New York, NY 10001,  by telephone at (800) 326-5897, or by email at ; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720, or by email at

    This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

    Precigen: Advancing Medicine with Precision

    Precigen (NASDAQ:PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies are designed to enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

    Cautionary Statement Regarding Forward-Looking Statements

    Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon Precigen's current expectations and projections about future events and generally relate to the proposed public offering. Various factors may cause differences between Precigen's expectations and actual results, including risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering. For further information on potential risks and uncertainties, and other important factors, any of which could cause Precigen's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in Precigen's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission.

    For more information, contact:

    Investor Contact:

    Steven Harasym

    Vice President, Investor Relations

    Tel: +1 (301) 556-9850

     

    Media Contact:

    Glenn Silver

    Lazar-FINN Partners

     



     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precigen-announces-pricing-of-112-5-million-public-offering-of-common-stock-301213003.html

    SOURCE Precigen, Inc.

    View Full Article Hide Full Article
View All Precigen Inc. News